Showing 13 contractssorted by Publication date (descending)with contracted value of GBP 29,345,794.00Supplier:astellas-ukCountry:United Kingdom ๐ฌ๐ง [๐ข ๐ ๐๏ธ]
| Description | Supplier | Buyer | Awarded amount | Date |
|---|---|---|---|---|
| Micafungin (Mycamine(r)). | Astellas | The Common Services Agency (more commonly known as | GBP 347,780.00 | 2017-09-21 |
| Micafungin (Mycamine(r)). | Astellas | The Common Services Agency (more commonly known as | GBP 347,780.00 | 2017-09-21 |
| Immunosuppressant Medicines. | Astellas | The Common Services Agency (more commonly known as | GBP 3,176,088.00 | 2017-05-24 |
| Enzalutamide (Xtandi(r)). | Astellas | The Common Services Agency (more commonly known as | GBP 8,800,000.00 | 2016-05-11 |
| Enzalutamide (Xtandi(r)). | Astellas | The Common Services Agency (more commonly known as | GBP 8,800,000.00 | 2016-05-11 |
| Supply of Micafungin (Mycamine). | Astellas | Golden Jubilee Hospital (National Waiting Times Ce | GBP 491,682.00 | 2013-11-13 |
| Immunosuppressant Medicines. | Astellas | Golden Jubilee Hospital (National Waiting Times Ce | GBP 3,002,464.00 | 2013-03-29 |
| NP41111 Immunosuppressant Medicines. | Astellas | The Common Services Agency (more commonly known as | GBP 730,000.00 | 2011-07-28 |
| NP41111 Immunosuppressant Medicines. | Astellas | The Common Services Agency (more commonly known as | GBP 730,000.00 | 2011-07-28 |
| NP41111 Immunosuppressant Medicines. | Astellas | The Common Services Agency (more commonly known as | GBP 730,000.00 | 2011-07-28 |
| NP41111 Immunosuppressant Medicines. | Astellas | The Common Services Agency (more commonly known as | GBP 730,000.00 | 2011-05-11 |
| NP41111 Immunosuppressant Medicines. | Astellas | The Common Services Agency (more commonly known as | GBP 730,000.00 | 2011-05-11 |
| NP41111 Immunosuppressant Medicines. | Astellas | The Common Services Agency (more commonly known as | GBP 730,000.00 | 2011-05-11 |
Data sources
Explore public procurement data with transparency. Access information on contracts, suppliers, and buying entities, and contribute to citizen oversight of public spending.

